Bedrijfsoverzicht
Theriva Biologics, Inc. is a clinical-stage biotechnology entity focused on the development of therapeutics designed to address cancer and related diseases within areas of high unmet medical need in the United States. The company operates within the Healthcare sector, specifically the Biotechnology industry, which implies a reliance on extensive research and development cycles and regulatory approval processes before products can reach commercialization. As of the latest reported data, the company holds a market capitalization of $10.59M and employs a workforce of 15 individuals. The combination of a market cap under $15 million and zero reported annual revenue indicates that Theriva Biologics is a micro-cap entity in the early stages of its commercial lifecycle, where value is derived primarily from intellectual property and clinical progress rather than current sales volume. This scale suggests the company is highly dependent on successful Phase 1 clinical trials and future capital raises to fund operations, as its lead product candidate, VCN-01, remains in Phase 1 clinical trials and has not yet generated commercial revenue.
Financiële gezondheid
Theriva Biologics reported a net income of $-25,249,000 and an EBITDA of $-14,912,000 for the trailing twelve months, while revenue figures are not available due to the lack of commercial sales. The significant gap between the reported net income and EBITDA reveals a substantial cost structure dominated by non-operating expenses, likely interest or other income/expense items, which depresses the bottom line beyond the core operating losses typical of clinical-stage biotechs. The company generated a free cash flow of $-5,976,500, indicating a continuous burn rate that requires external financing to sustain operations and advance its clinical programs. All three margin metrics—Gross Margin, Operating Margin, and Profit Margin—are reported at 0.0%, which reflects the absence of revenue to calculate profitability percentages rather than necessarily indicating zero cost efficiency in a traditional manufacturing sense. On the balance sheet side, the company holds $13.06M in cash against $2.63M in debt, resulting in a debt-to-equity ratio of 17.09, which appears high on paper but must be contextualized by the company's lack of earnings and reliance on equity financing. Despite the high debt-to-equity figure, the current ratio stands at 1.74, suggesting that the company maintains sufficient liquid assets relative to its short-term obligations to manage immediate liquidity needs. Return on Equity is reported at -137.8% and Return on Assets at -25.5%, metrics that mathematically reflect the company's current inability to generate positive returns on shareholder capital or assets due to its pre-revenue status and accumulated net losses.
Waarderingsbeoordeling
The P/E Ratio (TTM) is listed as N/A due to the negative earnings, while the Forward P/E is reported as -1.15, a metric that is often not meaningful for companies with negative projected earnings but serves as a standardized data point in financial databases. The Price to Book ratio is 0.54, indicating that the market values the company's equity at roughly half of its book value, which is common for distressed or early-stage biotechnology firms where market sentiment discounts future potential against current tangible assets. The Price to Sales ratio is N/A and the EV/EBITDA is -0.01, both figures highlighting that traditional valuation multiples based on sales or earnings power are not applicable until the company achieves positive financial performance. The stock has traded between a 52-Week High of $1.50 and a 52-Week Low of $0.16, meaning the current trading price sits significantly below the recent peak, reflecting the volatility and speculative nature of clinical-stage assets. The Beta value is 0.47, which indicates that the stock's price volatility is substantially lower than the broader market index, suggesting that the share price is less sensitive to general market movements and is driven primarily by company-specific clinical trial outcomes and biotech sector sentiment.
Growth & Income
The Revenue Growth (YoY) and Earnings Growth (YoY) are both listed as N/A, as the company has not yet generated consistent commercial revenue streams to calculate year-over-year expansion rates. In the absence of positive earnings, the concept of earnings growing faster or slower than revenue does not apply in a traditional sense, as the company is still in the investment phase of development rather than the growth phase of commercialization. Theriva Biologics does not pay dividends, evidenced by a Dividend Yield of N/A and a Payout Ratio of 0.0%, meaning the company retains all available resources, albeit currently negative, to reinvest into its clinical trials and drug development pipeline rather than distributing income to shareholders. Consequently, the overall growth and income profile of Theriva Biologics is characterized by zero current income generation and undefined growth rates until the lead product candidate transitions from clinical trials to commercial sale.